A Agilent Technologies Inc.

Agilent Announces Gen6 Software for BioTek Line of Microplate Readers

(NYSE: A) today announced the launch of new Gen6 software for all Agilent BioTek detection instruments. Featuring a broad range of prebuilt experiment templates for common applications, the new software provides automated optimization tools and improved navigation through built-in data analysis functions.

Modern laboratories house an array of sophisticated analytical instruments controlled by equally sophisticated – and often formidably complex – software. Straightforward instrument control interfaces that quickly and reliably connect users to essential results can significantly increase the speed and ease with which scientific research efforts move forward.

The design of the facilitates ‘walkup’ convenience for all users, regardless of experience level. The software also features an intuitive user interface that enables complete control of BioTek microplate readers for absorbance, fluorescence, and luminescence measurements in a variety of microplates for both endpoint and kinetic assays. Reading parameters, plate layout, and data analysis definition are easily established through a step-by-step process for both quantitative and qualitative assays. Additionally, well data and analysis results can be exported automatically or fully customized to suit data reporting requirements.

“The new Gen6 software for Agilent BioTek microplate readers delivers an improved user experience," said Caleb Foster, associate vice president of marketing for Agilent's Cell Analysis Division. “Agilent continues to develop innovative new plate readers to support our customers’ needs, driven by extensive user feedback. Gen6 is next-generation software providing new and seasoned users with the tools required for existing and future applications.”

Gen6 software is standard on all new Agilent BioTek microplate readers; existing users of Gen5 software can purchase an upgrade to Gen6.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, please subscribe to the Agilent . Follow Agilent on and .

EN
10/07/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Agilent Technologies, Inc.: Key facts and statistics - fiscal 2025

A summary company profile, detailing Agilent Technologies, Inc.’s business operations and financial highlights.

Agilent Technologies, Inc. - October 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Agilent Technologies, Inc.: Update to credit analysis

Our credit view of this issuer reflects its low financial leverage, against its high proportion of revenue from costly equipment sales, which has exposure to cyclical demand fluctuations

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Agilent Technologies, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 11 December 2025 in which we reassessed the appropriateness of the ratings in th...

Agilent Technologies Inc: 1 director

A director at Agilent Technologies Inc sold 2,600 shares at 149.812USD and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch